Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction

American Journal of Cardiology

Volumn 113, Issue 7, 2014, Pages 1198-1204

  Liu, Gang ^a   Zheng, Xin Xin ^a   Xu, Yan Lu ^a   Ru, Jie ^a   Hui, Ru Tai ^a   Huang, Xiao Hong ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG EFFECT; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR FUNCTION, LEFT; WORLD HEALTH;

EID: 84896034713     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.12.023     Document Type: Article

References (30)

1. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47: 332-337. (Pubitemid 43063250)
2. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-843. (Pubitemid 37022126)
3. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, Dyrbus K, Badzinski A, Mercik G, Zembala M, Wodniecki J, Rozek MM. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006;97:899-904.
4. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261. (Pubitemid 350190755)
5. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
6. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357-363.
7. Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients ≥65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 2008;101:217-222.
8. Roik M, Starczewska MH, Huczek Z, Kochanowski J, Opolski G. Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function - a preliminary report. Acta Cardiol 2008;63:683-692.
9. Tehrani F, Phan A, Chien CV, Morrissey RP, Rafique AM, Schwarz ER. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. Am J Cardiol 2009;103:829-833.
10. Ouzounian M, Tu JV, Austin PC, Chong A, Liu PP, Lee DS. Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J Card Fail 2009;15:241-248.
11. Tehrani F, Morrissey R, Phan A, Chien C, Schwarz ER. Statin therapy in patients with diastolic heart failure. Clin Cardiol 2010;339(suppl):e1-e5.
12. Gomez-Soto FM, Romero SP, Bernal JA, Escobar MA, Puerto JL, Andrey JL, Ruiz P, Gomez F. Mortality and morbidity of newly diagnosed heart failure treated with statins: a propensity-adjusted cohort study. Int J Cardiol 2010;140:210-218.
13. Lahoti A, Saeed W, Badri M, Gnall E, Sardar R, Zolty R. Impact of statins on long term mortality in heart failure with preserved ejection fraction (HFPEF). J Am Coll Cardiol 2012;59(suppl):e1010.
14. Quiros Lopez R, Garcia Alegria J, Martin Escalante MD, Trujillo Santos J, Villena Ruiz MA, Perea Milla E. Prognostic factors and longterm survival after initial diagnosis of heart failure. Med Clin (Barc) 2012;138:602-608.
15. Cosentino ER, Rinaldi ER, Santi F, Immordino V, Degli Esposti D, Bacchelli S, Veronesi M, Bentivenga C, Rosticci M, Cicero AF, Borghi C. Role of statins on mortality in patients with heart failure. High Blood Press Cardiovasc Prev 2012;19:174.
16. Kaneko H, Suzuki S, Yajima J, Oikawa Y, Sagara K, Otsuka T, Matsuno S, Kano H, Uejima T, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T. Clinical characteristics and longterm clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: a prospective cohort of Shinken Database 2004-2011. J Cardiol 2013;62:102-109.
17. Wells GA, Shea B,O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available at: http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp. Accessed October 8, 2012.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560. (Pubitemid 37088507)
19. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219. (Pubitemid 36143396)
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012. (Pubitemid 30214957)
21. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144-2150. (Pubitemid 35265382)
22. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
23. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016.
24. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008;168:721-727. (Pubitemid 351563955)
25. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-324. (Pubitemid 32666954)
26. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, Cittadini A, Cardone L, Coppola C, Cavuto L, Arcucci O, Sacca L, Avvedimento EV, Chiariello M. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002;106:2118-2124. (Pubitemid 35192819)
27. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-2363. (Pubitemid 40647072)
28. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002;106:2884-2887. (Pubitemid 35424736)
29. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-873. (Pubitemid 34174929)
30. Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, Oikawa S, Kawanishi S, Yamada Y, Yokota M. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 2006;69:726-735. (Pubitemid 43139735)